Senores Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Efficient capital deployment (ROCE 15.1%)
- Low debt relative to equity (D/E 0.4x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
SENORES · as of Sep 2026
| Category | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
| Promoters | 45.78% | 45.80% | 45.81% | 45.82% | 45.82% | 45.81% |
| FII | 3.66% | 4.28% | 3.35% | 3.64% | 6.62% | 6.01% |
| DII | 9.51% | 8.62% | 9.32% | 9.62% | 9.77% | 10.85% |
| Public | 41.03% | 41.30% | 41.54% | 40.92% | 37.78% | 37.32% |
Corporate Events
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
Latest News
All newsSenores Pharma reappoints MD Swapnil Shah
*Senores Pharma reappoints MD Swapnil Shah.* The board reappointed Mr. Swapnil Jatinbhai Shah as Managing Director. The decision was approved on October 13, 2026. No financial impact is expected from this routine corporate action. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Leadership
Senores Pharmaceuticals holds 9th Annual General Meeting.
*Senores Pharmaceuticals holds 9th Annual General Meeting.* The company released the scrutineer report and voting results from its AGM. No major corporate actions or financial announcements were disclosed. The event was procedural with no immediate market-moving updates. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Senores Pharmaceuticals issues general corporate updates
*Senores Pharmaceuticals issues general corporate updates.* The company filed routine updates with the NSE without disclosing specific financials or strategic changes. Details remain sparse, with no quantifiable impact indicated. Investors await further disclosures. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateUpdate
Senores Pharmaceuticals issues general corporate updates
*Senores Pharmaceuticals issues general corporate updates.* The company filed routine disclosures with the NSE, containing no major financial or operational announcements. Such updates typically include administrative or compliance-related information. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Senores Pharma to host analyst and investor meet
*Senores Pharma to host analyst and investor meet.* The company has announced a schedule for its upcoming investor interaction. Details on business outlook and performance may be discussed. No financial figures or major announcements disclosed yet. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorMeet
Senores Pharma publishes annual report dispatch notice
*Senores Pharma publishes annual report dispatch notice.* The company has released a newspaper publication confirming the pre-dispatch of its **Annual Report** for the upcoming Annual General Meeting. This is a routine compliance requirement under corporate filing norms. No financial or operational updates were disclosed. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AnnualReport
Senores Pharma to host analyst call for Q1FY27.
*Senores Pharma to host analyst call for Q1FY27.* The company will conduct an investor meet on **July 27, 2026**, to discuss quarterly performance. This event offers clarity on recent financials and management outlook. Investors may anticipate guidance or strategic updates. 📊 *STOCKS:* $SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Senores Pharmaceuticals publishes newspaper notice
Senores Pharmaceuticals Limited released a copy of its newspaper publication as part of regulatory compliance. The filing contains no financial or operational updates. Such disclosures are routine and typically informational in nature. No immediate market-moving developments were indicated. 📊 *STOCKS:* SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #CorporateFiling
Senores Pharma to host analyst and investor meet
*Senores Pharma to host analyst and investor meet.* The company has announced a schedule for its investor interaction. No financial updates or guidance changes were disclosed. Event aimed at enhancing institutional engagement. 📊 *STOCKS:* SENORES | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Earnings
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹175 Cr 2.3% | ₹171 Cr 5.6% | ₹162 Cr 17.4% | ₹138 Cr 21.1% | ₹114 Cr 10.7% | ₹103 Cr 2.0% | ₹101 Cr 26.3% | ₹80 Cr |
| Op. Profit | ₹47 Cr 6.0% | ₹50 Cr 0.0% | ₹50 Cr 47.1% | ₹34 Cr 78.9% | ₹19 Cr 26.9% | ₹26 Cr 13.0% | ₹23 Cr 9.5% | ₹21 Cr |
| OPM | 27.0% 6.9% | 29.0% 6.5% | 31.0% 24.0% | 25.0% 47.1% | 17.0% 32.0% | 25.0% 8.7% | 23.0% 14.8% | 27.0% |
| Net Profit | ₹37 Cr 8.8% | ₹34 Cr 13.3% | ₹30 Cr 42.9% | ₹21 Cr 16.7% | ₹18 Cr 12.5% | ₹16 Cr 23.1% | ₹13 Cr 18.2% | ₹11 Cr |
| EPS (₹) | 6.86 0.1% | 6.87 2.3% | 7.03 64.3% | 4.28 10.6% | 3.87 3.8% | 3.73 3.4% | 3.86 19.5% | 3.23 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | ₹633 Cr 59.0% | ₹398 Cr 85.1% | ₹215 Cr 514.3% | ₹35 Cr 150.0% | ₹14 Cr |
| Expenses | ₹464 Cr 50.2% | ₹309 Cr 78.6% | ₹173 Cr 652.2% | ₹23 Cr 91.7% | ₹12 Cr |
| Op. Profit | ₹168 Cr 86.7% | ₹90 Cr 114.3% | ₹42 Cr 223.1% | ₹13 Cr 550.0% | ₹2 Cr |
| OPM | 27.0% 17.4% | 23.0% 21.1% | 19.0% 47.2% | 36.0% 157.1% | 14.0% |
| Other Income | ₹47 Cr 147.4% | ₹19 Cr 533.3% | ₹3 Cr 25.0% | ₹4 Cr | ₹0 Cr |
| Interest | ₹25 Cr 13.6% | ₹22 Cr 144.4% | ₹9 Cr 350.0% | ₹2 Cr 100.0% | ₹1 Cr |
| Depreciation | ₹31 Cr 82.4% | ₹17 Cr 70.0% | ₹10 Cr 400.0% | ₹2 Cr 100.0% | ₹1 Cr |
| PBT | ₹159 Cr 123.9% | ₹71 Cr 184.0% | ₹25 Cr 108.3% | ₹12 Cr 1100.0% | ₹1 Cr |
| Tax % | 24.0% 41.2% | 17.0% 154.8% | -31.0% 196.9% | 32.0% 146.2% | 13.0% |
| Net Profit | ₹122 Cr 110.3% | ₹58 Cr 75.8% | ₹33 Cr 312.5% | ₹8 Cr 700.0% | ₹1 Cr |
| EPS (₹) | 25.05 96.9% | 12.72 23.4% | 10.31 20.0% | 8.59 750.5% | 1.01 |
| Div Payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Liabilities | |||||
| Equity Capital | ₹46 Cr 0.0% | ₹46 Cr 48.4% | ₹31 Cr 210.0% | ₹10 Cr 11.1% | ₹9 Cr |
| Reserves | ₹888 Cr 20.0% | ₹740 Cr 325.3% | ₹174 Cr 383.3% | ₹36 Cr 28.6% | ₹28 Cr |
| Borrowings | ₹342 Cr 8.6% | ₹315 Cr 22.1% | ₹258 Cr 309.5% | ₹63 Cr 320.0% | ₹15 Cr |
| Other Liabilities | ₹328 Cr 160.3% | ₹126 Cr 21.3% | ₹160 Cr 595.7% | ₹23 Cr 187.5% | ₹8 Cr |
| Total Liabilities | ₹1.6K Cr 30.7% | ₹1.2K Cr 97.3% | ₹622 Cr 374.8% | ₹131 Cr 122.0% | ₹59 Cr |
Assets | |||||
| Fixed Assets | ₹755 Cr 150.8% | ₹301 Cr 28.1% | ₹235 Cr 770.4% | ₹27 Cr 285.7% | ₹7 Cr |
| CWIP | ₹17 Cr 90.1% | ₹172 Cr 77.3% | ₹97 Cr 185.3% | ₹34 Cr 325.0% | ₹8 Cr |
| Investments | ₹4 Cr | ₹0 Cr | ₹0 Cr 100.0% | ₹16 Cr 6.7% | ₹15 Cr |
| Other Assets | ₹827 Cr 9.7% | ₹754 Cr 160.9% | ₹289 Cr 445.3% | ₹53 Cr 82.8% | ₹29 Cr |
| Total Assets | ₹1.6K Cr 30.7% | ₹1.2K Cr 97.3% | ₹622 Cr 374.8% | ₹131 Cr 122.0% | ₹59 Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating CF | ₹62 Cr 234.8% | ₹-46 Cr 76.9% | ₹-26 Cr 2500.0% | ₹-1 Cr 90.0% | ₹-10 Cr |
| Investing CF | ₹-121 Cr 71.8% | ₹-429 Cr 694.4% | ₹-54 Cr 12.5% | ₹-48 Cr 100.0% | ₹-24 Cr |
| Financing CF | ₹-1 Cr 100.2% | ₹573 Cr 558.6% | ₹87 Cr 89.1% | ₹46 Cr 27.8% | ₹36 Cr |
| Net Cash Flow | ₹-60 Cr 161.2% | ₹98 Cr 1125.0% | ₹8 Cr 366.7% | ₹-3 Cr 250.0% | ₹2 Cr |
| Free Cash Flow | ₹-203 Cr 0.0% | ₹-203 Cr 160.3% | ₹-78 Cr 62.5% | ₹-48 Cr 128.6% | ₹-21 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Debtor Days | 187d 64.0% | 114d 40.3% | 191d 16.2% | 228d 54.9% | 506d |
| Inventory Days | 130d 44.0% | 232d 26.1% | 184d 106.7% | 89d 34.1% | 135d |
| Days Payable | 340d 23.6% | 275d 50.5% | 556d 43.3% | 388d 19.8% | 324d |
| Cash Conv. Cycle | -24d 134.3% | 70d 138.5% | -182d 156.3% | -71d 122.4% | 317d |
| Working Capital Days | 132d 50.0% | 88d 650.0% | -16d 128.6% | -7d 101.9% | 359d |
| ROCE | 15.0% 36.4% | 11.0% 8.3% | 12.0% 33.3% | 18.0% | — |
Source: Screener.in · Lower days = better efficiency